Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest Down 15.3% in April

Posted by Maddie Sorensen on May 1st, 2024

Sol-Gel Technologies Ltd. (NASDAQ:SLGL – Get Free Report) was the recipient of a large drop in short interest during the month of April. As of April 15th, there was short interest totalling 9,400 shares, a drop of 15.3% from the March 31st total of 11,100 shares. Based on an average daily trading volume, of 31,300 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.1% of the shares of the company are sold short.

Sol-Gel Technologies Trading Down 18.7 %

SLGL stock opened at $0.71 on Wednesday. The company has a market capitalization of $19.85 million, a P/E ratio of -0.77 and a beta of 1.33. The business has a 50 day simple moving average of $1.00 and a 200-day simple moving average of $1.18. Sol-Gel Technologies has a twelve month low of $0.71 and a twelve month high of $4.05.

Sol-Gel Technologies (NASDAQ:SLGL – Get Free Report) last issued its quarterly earnings data on Wednesday, March 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.01). The business had revenue of $0.45 million for the quarter, compared to analysts’ expectations of $0.27 million. Sol-Gel Technologies had a negative return on equity of 61.52% and a negative net margin of 1,331.01%. Research analysts predict that Sol-Gel Technologies will post -0.67 EPS for the current fiscal year.

Institutional Trading of Sol-Gel Technologies

A hedge fund recently bought a new stake in Sol-Gel Technologies stock. Yelin Lapidot Holdings Management Ltd. bought a new stake in Sol-Gel Technologies Ltd. (NASDAQ:SLGL – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 229,178 shares of the company’s stock, valued at approximately $374,000. Yelin Lapidot Holdings Management Ltd. owned 0.99% of Sol-Gel Technologies at the end of the most recent quarter. Institutional investors own 26.18% of the company’s stock.

About Sol-Gel Technologies

(Get Free Report)

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.